A new report from No Patient Left Behind argues that foreign value assessments used by high-income countries such as Canada and Germany systematically undervalue innovative medicines by about 90%. The group says traditional health technology assessment methods—often anchored on outdated willingness-to-pay thresholds and quality-adjusted life year frameworks—mislead U.S. policymakers and risk reducing patient access.